Table 1.

Food and Drug Administration-Approved Indications for Bisphosphonates

Bisphosphonate	Indications
Alendronate10	Prevention and treatment of postmenopausal osteoporosis Treatment of male osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget disease
Clodronate5*	None
Etidronate11	Prevention and treatment of heterotopic ossification Treatment of Paget disease
Ibandronate12	Prevention and treatment of postmenopausal osteoporosis
Pamidronate13	Treatment of osteolytic bone metastases (breast cancer and multiple myeloma) Treatment of hypercalcemia of malignancy Treatment of Paget disease
Risedronate14	Prevention and treatment of postmenopausal osteoporosis Treatment of male osteoporosis Treatment of glucocorticoid-induced osteoporosis Treatment of Paget disease
Tiludronate15	Treatment of Paget disease
Zoledronic acid16,17	Treatment of bone metastases from solid tumors, including prostate cancer Treatment of multiple myeloma Treatment of hypercalcemia of malignancy Treatment of postmenopausal osteoporosis Treatment of Paget disease

^*Not commercially available in the United States.